Digitising supply chain operations
Veratrak to help CPO achieve digitsied end-to-end visibility of its supply chain.
Veratrak, a UK-based software provider dedicated to transforming supply chains across the life science industry, has announced that contract packaging organisation (CPO) Central Pharma has selected its platform to help it achieve digitised end-to-end visibility of its supply chain and improve collaboration.
The Veratrak platform provides companies with full transparency of their supply chains, ensures secure and compliant critical document transfer, as well as facilitating partner collaboration to drive operational performance.
Jason Lacombe, CEO at Veratrak said: “We are really pleased to be welcoming Central Pharma and their extensive customer and partner network to our platform.
“At present, all document approval and on-boarding processes at Central Pharma are running through email and internal working groups. By introducing our platform, we can help them to connect with their network, digitise these manual processes and secure their supply chain operations moving forward.”
Leveraging blockchain technology, the platform stores data as part of an immutable ledger and permits secure data sharing across supply chain partners.
By taking a proactive approach to cybersecurity, Veratrak has developed a system that generates an indisputable audit trail of all document processes and ensures GxP compliance.
Jason continued: “Our end goal is to move the industry from paper to platform and away from non-compliant methods, such as email. We are thrilled to be working with forward-thinking companies, such as Central Pharma to drive our industry towards a safer and more secure future.”
The Veratrak platform enables simple collaboration between multiple sites and across large customer networks. The data-driven methodology behind the platform also allows customers to access actionable insights, helping them to overcome operational inefficiencies they may not even be aware of.
Alwyn Smit, managing director at Central Pharma added: “By partnering with Veratrak we are taking the first step required to build a fully digital end-to-end supply chain network, that ensures data integrity and secure sharing of information between partners.
“We chose Veratrak because its platform was designed with the industry in mind. Its solution not only gives us control over our supply chain but also has the potential to add value to our operations. By using a collaborative platform that facilitates efficient workflow, we will be able to reduce lead times by improving order management.”
The Veratrak platform will be used across Central Pharma’s Bedford, UK site, with the aim of later being introduced to the CPO’s new site in Kerry, Ireland.
Alwyn continues: “As we supply products to over 60 countries and prepare to open our second site, Veratrak’s solution will help to ensure we continue to deliver high quality and on-time results for our customers. We are really excited about what this partnership will bring to both parties over the next year.”
The Veratrak platform is purpose-built for the life science industry and is being continuously developed by experts to provide a digital solution that solves unmet market challenges. The fast-growing company has recently doubled its team and onboarded other leading contract service providers to its platform.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.